CClinicalTrials.gg
RecruitingNCT07348666ViraSafeRCTUpdated Aug 12, 2026

A Just-in-time Adaptive Intervention for Suicide Safety Planning in Adolescents

An interventional study of ViraSafe: Treatment pushes and BRITE in Suicide, Mental Health Disorder and Anhedonia, sponsored by Ksana Health. Recruiting at 3 sites in United States. Open to participants aged 13 Years to 24 Years. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Ksana Health · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
13 Years to 24 Years
Sex
All
01

Study summary

Despite efforts to prevent suicide, US rates are climbing, and suicide is the second leading cause of death amongst youth. Digital tools, especially personal smartphones, are promising avenues to address these issues and can be used to increase engagement with effective interventions such as suicide safety planning. The BRITE suicide safety planning app was developed on evidence-based principles and has undergone rigorous formative development and effectiveness evaluations. However, to optimize its functionality, commercial viability, and scale its implementation, issues related to user engagement needed to be addressed. This 3 month Pragmatic Randomized Trial will evaluate the impact of the ViraSafe app-an enhanced version of the BRITE suicide safety planning app-on improving engagement with coping skills and safety planning among suicidal adolescents by comparing its intervention components to those of the original BRITE app.

Read the detailed description

ViraSafe is an augmented version of the BRITE app that integrates the BRITE coping skills and safety planning content into a module within the Vira behavior change platform. Vira, a digital behavior change platform developed by Ksana Health, consists of a smartphone app for patients, along with integrated web portals for practitioners and for healthcare administrators and supervisors. The platform collects self-report and passive data on smartphone usage patterns, such as language use, physical activity, sleep, social interactions, and screen time, and uses these insights to provide objective and continuous measurements of mental health indicators.

Upon downloading the Vira app and accessing the ViraSafe module, participants will complete a safety plan with their provider. Safety plan content will be editable and viewable throughout the intervention for both participants and their providers. Participants will be able to access the safety plan at any time in ViraSafe. Additionally, patients using ViraSafe will be prompted to complete a daily distress rating. ViraSafe uses automated algorithms (i.e., just in time adaptive intervention features) and user input from distress ratings to facilitate increased engagement with coping skills and pushes safety planning materials to users at periods of high risk (i.e., increases in emotional distress).

In addition to the just-in-time reminders (i.e., nudges) pushed automatically by the system, through the Vira Pro platform, practitioners can schedule just-in-time reminders (i.e., "nudges") to arrive in the user's phone to support their behavior change plan.

After undergoing study screening procedures and providing informed consent/assent, participants will complete the baseline assessment (60 minutes) which will occur virtually over video conference software or phone call.

Additional self-reports collected at patient visit will be requested through informed consent process as some overlap with what research team plans to administer. Self-reports will be retrieved for data analysis at the timepoints that align with the study timepoints. Self-reports will be administered by research staff if not available from a clinic's measurement-based care system.

Following Baseline assessments, participants will be randomized in a 1:1 allocation to receive ViraSafe or BRITE (50 in each arm). Randomization will be based on age, sex, and suicide symptoms. At a scheduled patient visit in their clinical settings, onboarding to assigned app will occur. Onboarding involves downloading their assigned app from Google Play Store or Apple App Store. Each app involves a trained clinician from their clinic setting collaboratively completing a safety plan. If a mental health clinician is not available for onboarding after Baseline, a research clinician will assist with onboarding.

At 1-month timepoint, participants will repeat the assessment interview (which will occur virtually over video conference software or phone call) and self-report measures with additional items assessing acceptability, usability, and satisfaction using the Technology Acceptance Model (TAM) and System Usability Scale (SUS) (total assessment duration: 60 minutes). At the 3-month timepoint, participants will repeat the assessment interview (which will occur virtually over video conference software or phone call) and self-report measures (total duration: 60 minutes).

20 adolescent participants or as many that are needed to reach saturation who received ViraSafe intervention arm will be selected to complete a qualitative exit interview to provide additional feedback on the intervention (60 minutes). The interview guide will be developed closer to the time of first exit interview and submitted for approval to the IRB prior to completing interviews.

02

Conditions studied

  • Suicide
  • Mental Health Disorder
  • Anhedonia

Keywords

  • depression
  • depressive disorder
  • mood disorder
  • mental disorders
  • suicidal behavior
  • suicidal thoughts
  • suicidal ideation
03

Who can participate

Ages eligible
13 Years to 24 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

Youth (minors):

  • 13-17 years old
  • Suicide attempt in the last year and ideation in the past month
  • English fluency and literacy
  • Parent or legal guardian willing and able to legally provide informed consent
  • Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan

Youth (adults)

  • 18-24 years old
  • Recent suicide attempt or ideation with a plan
  • English fluency and literacy
  • Receiving care at one of the study clinical settings with trained providers to onboard ViraSafe or BRITE safety plan.

Exclusion criteria

Exclusion Criteria:

Youth (minors):

  • Unable to read/understand English
  • Current manic or psychotic episode
  • Development disability precluding comprehension of study procedures
  • No routine access to a mobile phone, assessed by EHR review and during phone screen
  • No eligible parent or legal guardian to provide informed consent

Youth (adults):

  • Unable to read/understand English
  • Current manic or psychotic episode
  • Development disability precluding comprehension of study procedures
  • No routine access to a mobile phone, assessed by EHR review and during phone screen
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    ViraSafe

    The new augmented app that combines BRITE coping skills and safety planning into the Vira behavior change platform

    Behavioral: ViraSafe: Treatment pushes

  • Active comparator
    BRITE

    The original BRITE app that promotes self-monitoring and self-management by providing strategies to avoid or cope with triggers for suicidal urges and has been rigorously tested in clinical trials

    Behavioral: BRITE

Interventions

  • BehavioralViraSafe: Treatment pushes

    ViraSafe participants will complete a safety plan with their provider. Safety plan content will be editable and viewable throughout the intervention for both participants and their providers. Participants will be able to access the safety plan at any time in ViraSafe. Additionally, patients using ViraSafe will be prompted to complete a daily distress rating. ViraSafe uses automated algorithms (i.e., just in time adaptive intervention features) and user input from distress ratings to facilitate increased engagement with coping skills and pushes safety planning materials to users at periods of high risk (i.e., increases in emotional distress). In addition to the just-in-time reminders (i.e., nudges) pushed automatically by the system, through the Vira Pro platform, practitioners can schedule just-in-time reminders (i.e., "nudges") to arrive in the user's phone to support their behavior change plan.

  • BehavioralBRITE

    The BRITE app contains the teen's safety plan, links to videos of how to use coping strategies they indicated in their safety plan that have been useful for them (like guided mediation or deep breathing), a library of evidence-based and age-appropriate coping skills and strategies that the adolescent can learn more about, photos or videos that the adolescent has uploaded to the app, and includes a question asking them to rate their distress level in the moment: "What is your distress level right now?" (1 is "Least Distressed" to 5, which is "Most Distressed"). Then, the teen is asked to identify the feeling that fits their distress level via 12 emoji images: "Which feelings fit your distress level?" Based on adolescent's distress rate, the BRITE app suggests coping skills or "activities" for the adolescent to lower their distress level.

05

What researchers measure

Primary outcomes

  1. Proximal Engagement

    Engagement with the ViraSafe app (i.e., tapping on the push notification, patterns of accessing app features such as coping skills and safety plan) and BRITE app (daily dose rating, post rating after accessing coping skill, editing coping skill content)

    Time frame: 24 hours

  2. Engagement with the apps

    Engagement over the course of the trial will be measured through objective app usage metrics, including total number and frequency of features used.

    Time frame: 3 months

Secondary outcomes

  1. Technology Acceptance

    Mixed methods feedback on acceptability, usability, and satisfaction, including the System Usability Scale and items adapted from the Technology Acceptance Model (TAM). System Usability Scale: 10 items -- Brooke, J(1996) Technology Acceptance Model: 12 Items - Adapted from Davis, (1989) Participants rate the extent to which they agree with each statement by circling a number from one to seven arranged horizontally beneath anchor point descriptions "Strongly Agree," "Neutral," and "Strongly Disagree.

    Time frame: 3 months

  2. Suicide Risk Factors: Columbia Suicide Severity Rating Scale (CSSRS)

    Changes in suicide risk factors from baseline to 3 months assessed through the Columbia Suicide Severity Rating Scale (CSSRS). The C-SSRS is an assessment of suicidal thoughts and behaviors in clinical and research settings. The C-SSRS consists of 16 questions about suicidal thoughts and behaviors (the first 10 questions comprise the ideation subscale and the last 6 comprise the behavior subscale). This 5-item subscale ranges from a minimum of 0 (corresponding to no suicidal ideation) to a maximum of 5 (representing active suicidal ideation with plan and intent).

    Time frame: 3 months

  3. Suicidal Risk Factors: Reason for Living

    The Reasons for Living (RFL) Inventory is a 48-item instrument that measures a range of beliefs potentially important as reasons for not committing suicide. The items are rated on 6-point Likert type scales based on how important each reason would be for living if suicide was contemplated (1 = not at all important; 6 = extremely important). The total score is calculating by calculating the mean of the item scores and multiplying the result by 48. Total scores can only be calculated if a participant answers at least 38 items.

    Time frame: 3 months

Other outcomes

  1. Depressive Symptoms: Mood and Feelings Questionnaire (MFQ)

    Changes in self-reported depressive symptoms from baseline to 3 months, assessed through the Mood and Feelings Questionnaire (MFQ). The MFQ is a 13-item self-report questionnaire used to screen for depressive in children and young people. Items are rated on a 3-point Likert scale (not true = 0; sometimes true = 1; not true = 2). Scores are calculated by summing the point values on each response. Total MFQ scores range from 0 to 26, with higher scores suggesting greater severity in depressive symptoms.

    Time frame: 3 months

  2. Anxiety Symptoms: the Screen for Anxiety Related Emotional Disorders (SCARED)

    Changes in self-reported anxiety symptoms from baseline to 3 months, assessed through the Screen for Anxiety Related Emotional Disorders (SCARED) The SCARED is a 5-item self-report questionnaire used to screen for childhood anxiety disorders including general anxiety disorder, separate anxiety disorder, panic disorder, and social phobia. Items are rated on a 3-point Likert scale from 0 to 2 and summed to yield a total score. Total scores range from 0 to 10. Higher scores indicate greater anxiety.

    Time frame: 3 months

06

Study locations

2 of 3 sites recruiting
  • Ksana Health Inc
    Eugene, Oregon 97405, United States
    Not yet recruiting
  • STAR Center, Western Psychiatric Institute & Clinic
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
  • University of Pittsburgh
    Pittsburgh, Pennsylvania 15213, United States
    Recruiting
07

Registry details

Key details

Study ID
NCT07348666
Lead sponsor
Ksana Health
Collaborators
National Institute of Mental Health (NIMH), University of Pittsburgh Medical Center
Responsible party
Sponsor
First posted
Jan 16, 2026
Start date
Jun 18, 2026
Primary completion
Dec 1, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 12, 2026

Study contacts

Stephanie Stepp, PhD
Contact
steppsd@upmc.edu
412-383-5051

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion